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Introduction: Inflammatory, autoimmune and metabolic disorders have been associated with alterations in
osteopontin (OPN) serum levels. Furthermore, elevated serum levels of OPN were reported from a small cohort
of patients with sepsis. We therefore analyzed OPN serum concentrations in a large cohort of critically ill medical
patients.
Methods: A total of 159 patients (114 with sepsis, 45 without sepsis) were studied prospectively upon admission to
the medical intensive care unit (ICU) as well as after 3 days of ICU treatment and compared to 50 healthy controls.
Clinical data, various laboratory parameters as well as investigational inflammatory cytokine profiles were assessed.
Patients were followed for approximately 1 year.
Results: We found significantly elevated serum levels of OPN at admission to the ICU and after 3 days of treatment in
critically ill patients compared to healthy controls. OPN concentrations were related to disease severity and significantly
correlated with established prognosis scores and classical as well as experimental markers of inflammation and
multi-organ failure. In the total cohort, OPN levels decreased from admission to day 3 of ICU treatment. However,
persistently elevated OPN levels at day 3 of ICU treatment were a strong independent predictor for an unfavorable
prognosis, with similar or better diagnostic accuracy than routinely used markers of organ failure or prognostic
scoring systems such as SAPS2 or APACHE II score.
Conclusions: Persistently elevated OPN serum concentrations are associated with an unfavourable outcome in
patients with critical illness, independent of the presence of sepsis. Besides a possible pathogenic role of OPN in
critical illness, our study indicates a potential value for OPN as a prognostic biomarker in critically ill patients during
the early course of ICU treatment.Introduction
Sepsis and septic shock represent major causes of
mortality in patients referred to intensive care units
[1]. Sepsis is defined by a Systemic Inflammatory Response
Syndrome (SIRS) in the context of infection [2]. This
response is characterized by both pro-inflammatory and
anti-inflammatory phases and involves the expression and
secretion of distinct pro- and anti-inflammatory mediators
such as cytokines and chemokines by different immune
and parenchymal cells [3]. Despite the rapid progresses of* Correspondence: frank.tacke@gmx.net; mark.luedde@uksh.de
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of chemokines and cytokines, there is a high demand for
new biomarkers that can help to better risk stratify patients
and assist clinical decision-making in allocating resources
of intensive care treatment [4].
Osteopontin (OPN) represents a phosphorylated acidic
glycoprotein that is involved in a broad variety of
physiological and pathological processes such as cancer,
fibrosis, inflammation and heart disease [5–7]. Regarding
inflammatory processes, OPN acts as a chemotactic
factor for T cells, macrophages or neutrophils and
modulates the function and differentiation of these
inflammatory cells [8]. Moreover, mediators of sepsis
and inflammation, including tumour necrosis factor
(TNF) and interleukin (IL)-1, stimulate the expression of
OPN on a transcriptional level, which appears critical forss article distributed under the terms of the Creative Commons Attribution
by/4.0), which permits unrestricted use, distribution, and reproduction in
operly credited. The Creative Commons Public Domain Dedication waiver
ro/1.0/) applies to the data made available in this article, unless otherwise stated.
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mation and infection [9]. Consequently, elevated serum
and tissue levels of OPN were found in different diseases
associated with systemic or focal inflammation, such as
tuberculosis [10], multiple sclerosis [11], lupus erythe-
matosus [12] and Crohn’s disease [13], thus suggesting
that circulating OPN may hold potential as a biomarker
for inflammatory and infectious diseases. Recently, OPN
has been introduced as a novel biomarker in cardiac
diseases, predicting the prevalence and prognosis of
chronic and acute congestive heart failure and pulmonary
hypertension [14–17].
Despite the emerging roles of OPN in the regulation
of inflammation and immunity, its functional involvement
in systemic infections remains to be elucidated. Moreover,
the diagnostic and prognostic value of OPN measure-
ments in critically ill patients is currently unclear [18]. We
therefore conducted a large study with critically ill patients
at a medical intensive care unit (ICU) and performed
longitudinal measurements of OPN serum concentrations
during the first days of ICU treatment. The aim of this
study was to address the regulation and diagnostic value
of OPN serum concentrations in critical illness, sepsis
and/or multi-organ failure. Finally, we assessed whether
OPN serum levels can serve as a prognostic predictor for




Age median (range) (years) 66 (20–90)
APACHE II score median (range) 18.5 (2–40)
SAPS2 score median (range) 44 (9–80)
ICU days median (range) 9 (1–70)
Death during ICU (%) 25.8
Death during ICU or follow-up (%) 46.5
Ventilation yes (%) 74.2
Body mass index (BMI) 25.4 (15.9–59.5)
Creatinine median (range) (mg/dl) 1.4 (0.2–21.6)
Albumin median (range) (g/l) 27 (6–44)
WBC median (range) (x103/μl) 12.5 (0.1–208)
CRP median (range) (mg/dl) 140 (5–230)
Procalcitonin median (range) (μg/l) 1.2 (0.1–182.6)
Interleukin 6 median (range) (pg/ml) 97 (2–26000)
Tumour necrosis factor median (pg/ml) 26 (4.1–4330)
INR 1.17 (0.94–4.64)
Osteopontin at admission median (ng/ml) 3358.5 (25.2–5884.4
Osteopontin at day 3 median (ng/ml) 1981.8 (13.9–3613.9
APACHE Acute Physiology and Chronic Health Evaluation, CRP C-reactive protein, IC
Physiology Score, WBC white blood cell countMethods
Study design and patient characteristics
A total of 159 consecutive patients (99 male, 60 female;
median age 66 years, range 20–90 years) that were
admitted to the general Internal Medicine ICU at the
University Hospital RWTH Aachen were enrolled into
this study (Table 1). Patients, who were expected to have
a short-term (<72 h) intensive care treatment due to
post-interventional observation or acute intoxication,
were not included into this study, following previously
published practice [19, 20]. The medium length of stay
at the ICU was 9 days (range 1–70 days). Patient data,
clinical information and blood samples were collected
prospectively. The clinical course of patients was observed
in a follow-up period by directly contacting the patients,
the patients’ relatives or their primary care physician.
Patients that met the criteria proposed by the American
College of Chest Physicians and the Society of Critical
Care Medicine Consensus Conference Committee for
sepsis, severe sepsis and septic shock were categorized as
sepsis patients, the others as non-sepsis patients [21, 22].
Patients displaying a body mass index (BMI) of >30 kg/m2
at ICU admission (prior to any treatment) were defined as
obese. Patients with a medical history of type 2 diabetes
and a concomitant intake of diabetes-related medication
were defined as diabetics. As a control population, weNon-sepsis Sepsis
45 114
28/17 71/43
63 (20–85) 67 (21–90)
16.5 (2–31) 19 (3–40)
50 (30–80) 44 (9–65)




25.2 (15.9–40.5) 25.6 (16.4–59.5)
1 (0.2–7.9) 1.6 (0.2–21.6)
29.5 (18.7–44) 25.2 (6–41)
12.5 (1.8–27.3) 12.8 (0.1–208)
17 (5–230) 186 (5–230)
0.2 (0.1–36.5) 3.1 (0.1–182.6)
22 (4.5–250) 135 (2–26000)
14 (4.1–35) 35 (9.6–430)
1.14 (0.95–3.45) 1.18 (0.94–4.64)
) 3166.9 (36.3–5782.6) 3504.8 (25.2–5884.4)
) 1997.6 (361.7–3577.0) 1948.7 (13.9–3613.9)
U intensive care unit, INR international normalized ratio, SAPS Simplified Acute
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blood counts, C-reactive protein (CRP) and liver enzymes.
The study protocol was approved by the local ethics
committee and conducted in accordance with the ethical
standards laid down in the Declaration of Helsinki
(ethics committee of the University Hospital Aachen,
RWTH University, Aachen, Germany, reference number
EK 150/06). Written informed consent was obtained from
the patient, his or her spouse or the appointed legal
guardian.
Determination and definitions of relevant parameters in
critically ill patients
Serum was obtained at admission to the ICU before
therapeutic intervention. For 65 patients, follow-up mea-
surements were available at day 3 and day 7 of ICU
treatment. All samples were immediately placed on ice,
centrifuged, and the serum samples were stored at −80 °C.
Interleukin 6 (IL-6), IL-10, TNF, procalcitonin (PCT),
soluble urokinase plasminogen activator receptor (suPAR),
NTproCNP, ghrelin, hyaluronic acid, a proliferation-
inducing ligand (APRIL) and micro ribonucleic acid
(miRNA)-133a were measured as described previously
[23–29]. Glomerular filtration rates (GFR) were calculated
on basis of serum cystatin C levels. ICU mortality was
defined as death on ICU; overall mortality included
death at the ICU or during the observation period
(after discharge from ICU and hospital) [23–29].
Determination of osteopontin serum concentrations
by ELISA
Osteopontin (OPN) serum concentrations were analysed
using a commercial enzyme immunoassay according to
the manufacturer’s instructions (Immuno-Biological
Laboratories, Minneapolis, MN, USA, Code No. 27158).
Statistical analysis
All statistical analyses were performed with SPSS (SPSS
Inc., Chicago, IL, USA) as previously described [25, 30].
In the tables, data are displayed as median and range
considering the skewed distribution of most parameters.
Differences between two groups were assessed by
Mann–Whitney U test, and multiple comparisons
between more than two groups have been conducted
by Kruskal-Wallis ANOVA and Mann–Whitney U
test for post hoc analysis. Box plot display a statistical
summary of the median, quartiles and extreme values.
The whiskers extend from the minimum to the maximum
value excluding outside and far out values, which are dis-
played as separate points. An outside value (indicated by
an open circle) was defined as a value that is smaller than
the lower quartile minus 1.5 times the interquartile range,
or larger than the upper quartile plus 1.5 times the inter-
quartile range. A far out value was defined as a value thatis smaller than the lower quartile minus three times the
interquartile range, or larger than the upper quartile plus
three times the interquartile range. All values, including
“outliers”, have been included for statistical analyses.
Correlations between variables have been analysed using
the Spearman correlation tests, where values of p <0.05
were considered statistically significant. The prognostic
value of the variables was tested by univariate and
multivariate analysis in the Cox regression model.
Kaplan-Meier curves and log-rank test calculations
were performed to display the impact on survival.
Receiver operating characteristic (ROC) curve analysis
and the derived area under the curve (AUC) statistic
provide a global and standardized appreciation of the
accuracy of a marker or a composite score for predicting an
event. ROC curves were generated by plotting sensitivity
against 1-specificity. Optimal cutoff points were calculated
with the highest Youden Index, also positive likelihood
ratios (LHR+), negative likelihood ratios (LHR-) and diag-
nostic odds ratios for this cutoffs, as previously described
by Ray et al. [31].
Results
Osteopontin serum concentrations are elevated in
critically ill patients
Serum samples of critically ill patients were analysed at
admission (that is, before specific therapeutic interven-
tions) to the ICU and after 3 days of treatment. As shown
in Fig. 1a, patients had significantly higher OPN serum
concentrations at ICU admission as compared to healthy
controls. Of note, high serum levels of OPN were
associated with the severity of disease, since patients
with high Acute Physiology and Chronic Health
Evaluation (APACHE) II scores (>10) displayed a further
increase in circulating OPN levels (median 3497.41 ng/ml,
range 25.19–5884.44 ng/ml) compared to patients with
low APACHE II scores (median 2157.59 ng/ml, range
36.30–4634.44 ng/ml; p = 0.005; Fig. 1b).
Serum levels of OPN can be influenced by metabolic
disorders such as obesity and diabetes [32]. As these
comorbidities might represent important confounding
factors in medical patients admitted to the ICU, we
performed subgroup analyses in our cohort. Serum
OPN levels were even slightly reduced in patients
with pre-existing type 2 diabetes upon admission to
the ICU and did not vary dependent on the presence of
obesity (Fig. 1c, d). In addition, no correlations were found
between OPN concentrations and patients’ age or sex
(not shown). These data indicate that elevated OPN
levels indeed primarily relate to disease severity in
critically ill patients.
Based on a recent pilot study suggesting that OPN
might represent a novel biomarker for predicting sepsis
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Fig. 1 Serum osteopontin concentrations of critically ill patients at ICU admission. a Serum OPN concentrations at admission to the medical ICU
were determined by ELISA and revealed significantly (p <0.001, U test) higher OPN levels in critically ill patients as compared with healthy
controls. b Serum OPN levels at admission to the medical ICU are significantly (p = 0.005, U test) elevated in critically ill patients with high initial
Acute Physiology and Chronic Health Evaluation (APACHE) II scores (>10) compared to patients with low APACHE II scores (≤10). c Serum OPN
concentrations at admission to the ICU are significantly lower in patients with type 2 diabetes. d Serum OPN concentrations at admission to the
medical ICU are independent of the presence of obesity in critically ill patients. e Patients that fulfilled sepsis criteria displayed no further
increases in OPN serum levels at admission to the medical ICU. f OPN serum concentrations did not differ with regard to the disease aetiology in
critically ill patients. pulmo, pulmonal; abd, abdominal; uro, urological; cirrh, cirrhosis; c.p., cardiopulmonary. Box plot are displayed, where the bold
line indicates the median per group, the box represents 50 % of the values, and horizontal lines show minimum and maximum values of the
calculated non-outlier values; asterisks and open circles indicate outlier values. *p <0.05, **p <0.01, ***p <0.001. ELISA enzyme-linked immunosorbent
assay, ICU intensive care unit, OPN osteopontin
Table 2 Disease aetiology of the study population
Sepsis Non-sepsis
114 (71.7) 45 (28.3)
Aetiology of sepsis critical illness





Aetiology of non-sepsis critical illness
n (%)
Cardiopulmonary disease 14 (8.8)
Decompensated liver cirrhosis 10 (6.3)
Non-sepsis other 21 (13.2)
Roderburg et al. Critical Care  (2015) 19:271 Page 4 of 13serum OPN differed between ICU patients with or with-
out sepsis. Among the 159 critically ill patients enrolled
into this study, 114 patients fulfilled the criteria of sepsis
(Table 2) [21, 22]. Within the sepsis cohort, pneumonia
represented the predominant aetiology of critical illness
(n = 62), while most patients with non-septic diseases
suffered from cardiovascular diseases (n = 14) followed by
decompensated liver cirrhosis (n = 10). Other aetiologies
for non-septic disease included gastrointestinal (n = 6) and
non-gastrointestinal (n = 5) bleedings, intoxications
(n = 2), acute pancreatitis (n = 4) and diabetic ketoacidosis
(n = 4). In contrast to the previous study [18], we found
only a moderate increase in OPN serum concentrations at
admission in patients with sepsis compared to patients
without septic disease (Fig. 1e). Moreover, when the impact
of the underlying aetiology was analysed no significant dif-
ferences became apparent between the different subgroups
both in septic as well as in non-septic patients (Fig. 1f).
Roderburg et al. Critical Care  (2015) 19:271 Page 5 of 13Kinetics of osteopontin serum concentrations during
early ICU treatment
We next analysed the kinetics of OPN serum concentra-
tions during the first 3 days of ICU treatment. Interestingly,
despite remaining elevated compared to healthy controls,
longitudinal OPN measurements revealed overall a strong
and significant decrease between admission and day 3
(Fig. 2a). Of note, this was observed for the total cohort of
all critically ill patients as well as for the subgroup of sepsis
and non-sepsis patients (not shown).
We next compared OPN serum levels at day 3 of ICU
treatment between the different predefined subgroups of
ICU patients, namely low vs. high APACHE II scores
(Fig. 2b), pre-existing diabetes (Fig. 2c), obesity (Fig. 2d),
sepsis (Fig. 2e), or different disease aetiologies (Fig. 2f ).
None of these subgroup analyses revealed significantly


































































































Fig. 2 Serum osteopontin concentrations of critically ill patients after 3 day
treatment were analysed by ELISA. In the total patient cohort, OPN levels w
the ICU (p <0.001, U test). b Serum OPN levels after 3 days of ICU treatmen
according to the initial Acute Physiology and Chronic Health Evaluation (AP
(≤10). c Serum OPN concentrations at day 3 of ICU treatment are independ
at day 3 of ICU treatment are independent on the presence of obesity. e P
OPN serum levels at day 3 of ICU treatment compared to patients with no
to the disease aetiology in critically ill patients. pulmo, pulmonal; abd, abdo
are displayed, where the bold line indicates the median per group, the box
maximum values of the calculated non-outlier values; asterisks and open cir
***p <0.001. ELISA enzyme-linked immunosorbent assay, ICU intensive care uOsteopontin levels at admission to the ICU and after
3 days of ICU treatment are correlated to markers of
organ function, inflammation and prognosis scores
To determine factors possibly promoting elevated
OPN concentrations in critically ill patients, correlation
analyses with extensive sets of laboratory parameters were
performed. These analyses revealed that both OPN levels
at admission as well as after 3 days of ICU treatment were
significantly associated with laboratory markers routinely
used in the assessment of organ dysfunction. High OPN
levels correlated to decreased renal function assessed by
the GFR of cystatin C, elevated creatinine and urea serum
concentrations (Fig. 3; Table 3). In addition to renal
dysfunction, increased OPN levels at day 3 were also
significantly correlated with decreased markers of liver
synthesis capacity, such as albumin, pseudocholinesterase
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Fig. 3 Association of osteopontin serum concentrations with serum levels of experimental markers of critical illness. a-e Serum OPN
concentrations in ICU patients are correlated with previously reported experimental biomarkers of critical illness and sepsis as indicated.
Spearman rank correlation test, correlation coefficient r, and p values are given. ICU intensive care unit, OPN osteopontin
Roderburg et al. Critical Care  (2015) 19:271 Page 6 of 13We also detected an association to indicators of cholesta-
sis, namely bilirubin, gamma-glutamyl-transpeptidase and
alkaline phosphatase (Table 3). Furthermore, serum OPN
concentrations were closely correlated to markers of
systemic inflammation in critically ill and sepsis patients,
such as CRP, PCT, IL-6 and TNF (Table 3). Moreover, we
observed a strong and significant correlation between
OPN serum levels at day 3 and markers for dysregulated
vital signs such as ventilation settings, serum pH and
lactate levels. Consequently, we found a strong associ-
ation of OPN serum concentrations at ICU admission
and after 3 days of ICU treatment with established
clinical scores like APACHE II, Sequential Organ Failure
Assessment (SOFA) and Simplified Acute Physiology
Score (SAPS2) (Fig. 3; Table 3). This important finding
was further substantiated by significant correlations
between OPN levels and experimental markers for
organ failure and prognosis at the ICU such as APRIL,
miRNA-133a, suPAR and NTproCNP, while no significant
correlations with ghrelin, resistin and adiponectin were
found (Fig. 3; Table 3).
Recent studies revealed a strong association between
OPN levels and cardiac failure [14, 17]. In our cohort
we were able to confirm an association between brain
natriuretic peptide (BNP) and OPN serum levels at
admission to the ICU. Unfortunately, in our cohort of
patients, BNP concentrations were only analysed in
66 patients.Elevated osteopontin concentrations are associated with
ICU and overall survival
Based on the clear associations of serum OPN with
inflammatory markers, organ dysfunction and prognostic
clinical scores, we hypothesized that OPN measurements
could predict the mortality risk in critically ill medical
patients. We therefore first compared OPN serum con-
centrations at admission as well as after 3 days of ICU
treatment in patients that died during the ICU treatment
to those from survivors. Interestingly, patients that died
on ICU displayed higher serum OPN concentrations at
day 3, but not at admission, compared to survivors
(Fig. 4a, b). High OPN levels at day 3 were a strong
prognostic predictor for mortality at the ICU and showed
a comparable prognostic accuracy like established multifac-
torial scores such as SAPS2 score (Fig. 4c) and APACHE II
(not shown). We extended our ROC curve analysis and
compared the prognostic value of OPN measurements for
ICU mortality with that of serum levels of CRP and PCT
representing established markers for systemic inflamma-
tion or creatinine, bilirubin and INR representing estab-
lished markers for organ failure, respectively. This analysis
revealed a superior performance of OPN measurements
for prediction of patients prognosis compared to all of
these single markers (Fig. 4d).
We next applied the approach of Ray et al. [31] to
determine an optimal threshold with the highest Youden
Index for OPN levels predicting the patients’ mortality
Table 3 Correlations of osteopontin serum concentrations with other laboratory markers
Osteopontin at admission vs. laboratory
markers at admission day
Osteopontin at day 3 vs. laboratory
markers at admission day
Osteopontin at day 3 vs.
laboratory markers at day 3
r p r p r p
Markers of inflammation
CRP 0.306 0.001 0.202 0.033 0.050 0.601
Procalcitonin 0.378 0.006 0.295 0.010 0.620 <0.001
IL-10 −0.066 0.761 0.300 0.040 NA
IL-6 −0.131 0.629 0.081 0.612 0.153 0.464
Markers of organ function
Creatinine 0.258 0.006 0.307 0.001 0.363 <0.001
Cystatin 0.248 0.266 0.286 0.036 0.389 0.019
GFR −0.235 0.047 −0.350 0.002 −0.390 0.001
AST 0.116 0.268 0.318 0.001 0.275 0.009
ALT 0.042 0.662 0.307 0.001 0.226 0.017
GLDH −0.031 0.773 0.247 0.018 0.342 0.003
Bilirubin total 0.120 0.210 0.210 0.027 0.279 0.003
GGT 0.140 0.144 0.301 0.001 0.284 0.003
PCHE −0.294 0.005 −0.159 0.126 −0.149 0.185
Albumin −0.326 0.019 −0 206 0.090 −0.358 0.002
Urea 0.315 0.001 0.317 0.001 0.272 0.004
Iono lactate 0.040 0.696 0.349 <0.001 0.385 <0.001
LDH 0.210 0.027 0.379 <0.001 0.333 <0.001
BNP 0.224 0.045 NA NA
Fibrinogen 0.323 0.191 −0.269 0.057 −0.461 0.005
Clinical scoring
APACHE II 0.292 0.012 0.230 0.036 0.294 0.062
SAPS2 0.800 0.104 0.387 0.008 0.312 0.031
SOFA 0.387 0.003 0.486 0.003 0.512 0.002
Experimental sepsis markers
APRIL 0.258 0.040 0.325 0.005 NA
miR-133 0.293 0.024 0.404 0.001 NA
NTproCNP 0.284 0.003 0.325 0.001 0.395 <0.001
suPAR 0.331 0.001 0.396 <0.001 0.393 <0.001
Leptin −0.343 0.101 −0.015 0.918 NA
Leptin receptor −0.249 0.241 0.260 0.075 NA
Adiponectin 0.083 0.700 0.305 0.035 NA
Ghrelin 0.058 0.786 −0.109 0.460 NA
Resistin 0.205 0.336 0.226 0.122 NA
Other
C-peptide 0.557 0.009 0.107 0.439 0.316 0.061
Iono BZ −0.181 0.078 0.200 0.045 0.139 0.166
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Table 3 Correlations of osteopontin serum concentrations with other laboratory markers (Continued)
Survival time −0.002 0.989 −0.342 0.017 −0.342 0.017
Protein −0.350 0.003 −0.344 0.001 −0.278 0.059
Ventilation time total 0.151 0.141 0.212 0.032 0.212 0.032
NA not assessed, ALT alanine aminotransferase, APACHE Acute Physiology and Chronic Health Evaluation, APRIL, a proliferation-inducing ligand, AST aspartate
aminotransferase, BNP brain natriuretic peptide, CRP C-reactive protein, GFR glomerular filtration rate, GGT gamma-glutamyl transpeptidase, GLDH glutamate
dehydrogenase, IL interleukin, LDH lactate dehydrogenase, PCHE pseudocholinesterase, PCT procalcitonin, SAPS Simplified Acute Physiology Score, SOFA Sequential
Organ Failure Assessment, SuPAR soluble urokinase-type plasminogen activator receptor
Roderburg et al. Critical Care  (2015) 19:271 Page 8 of 13during ICU treatment. This analysis revealed that an
OPN concentration of 2148 ng/ml displayed the best
sensitivity and specificity to predict prognosis at the
ICU. Furthermore, we calculated the likelihood ratios
and diagnostic odds ratio for this cutoff (Table S1 in
Additional file 1) supporting our hypothesis that
OPN measurements might be suitable for predicting
patients’ prognosis. Based on this value we performed
Kaplan-Meier survival analysis, showing significantly
improved ICU survival of critically ill patients with
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Fig. 4 Prediction of ICU mortality by osteopontin serum concentrations. a
died during the course of ICU treatment compared to those that survived.
significantly higher in patients that died during the course of ICU treatmen
displayed, where the bold line indicates the median per group, the box rep
maximum values of the calculated non-outlier values. c ROC) curve analyse
treatment for ICU survival (AUC 0.793) with that of the initial SAPS2 – score
analyses comparing the prognostic value of OPN levels at day 3 of ICU trea
CRP (AUC 0.447), bilirubin (AUC 0.631), INR (AUC 0.667) and creatinine (AUC
with OPN levels below 2148 ng/ml had a decreased ICU mortality as comp
given in the figure. ***p <0.001. AUC area under the curve, CRP C-reactive p
OPN osteopontin, ROC receiver operating characteristic, SAPS Simplified Acuwith higher OPN concentrations at day 3 (Fig. 4e). Of
note, when Kaplan-Meier curves were performed with
different cutoffs such as OPN levels of the upper
quartile of measurements or the clinically more con-
venient threshold of 2500 ng/ml, high OPN levels
were consistently associated with an impaired progno-
sis (Figure S1 in Additional file 2). In line, survivors
displayed a tendency towards a stronger decrease in OPN
serum concentrations from admission to day 3 compared
to non-survivors (not shown). Based on post hoc analyses,
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s comparing the prognostic value of OPN levels at day 3 of ICU
(AUC 0.776) and day 3 SAPS2 –score (AUC 0.781). d ROC curve
tment for ICU survival (AUC 0.725) with that of WBC (AUC 0.431),
0.632). e Kaplan-Meier survival curves of ICU revealed that patients
ared to patients with higher OPN serum concentrations. p values are
rotein, ICU intensive care unit, INR international normalized ratio,
te Physiology Score, WBC white blood cell count
Roderburg et al. Critical Care  (2015) 19:271 Page 9 of 13additional cutoffs to detect ICU mortality. An OPN level
of 2786 ng/ml is the cutoff level corresponding to a
high specificity (sensitivity: 0.38; specificity 0.85), while
1653 ng/ml is the OPN cutoff value corresponding to a
high sensitivity (sensitivity: 0.85; specificity 0.36; Table S1
in Additional file 1).
To further substantiate these results on a potential prog-
nostic value of OPN measurements we next performed a
multivariate Cox regression analysis including markers of
inflammation/infection (CRP, white blood cell count
(WBC)), hepatic (bilirubin, INR) and renal (creatinine)
function at day 3, OPN was identified as an independent
significant prognostic parameter to predict ICU survival
(Table 4).
In our cohort of critically ill patients, 25.8 % died at
the ICU, while the overall mortality rate increased to
46.5 % during the (post-ICU/post-hospital) observation
period. Patients that died during long-term follow-up
showed a trend towards higher initial OPN levels than
survivors; strikingly, serum OPN levels at day 3 were
significantly higher levels in patients that died during
follow-up than for surviving patients (Fig. 5a, b). ROC
curve analysis revealed a rather low prognostic power of
OPN for predicting long-term mortality (Fig. 5c), which
was still superior to that of CRP and PCT as established
markers of SIRS/sepsis or other markers of organ failure
(Fig. 5d). Considering that high OPN was associated with
overall mortality by Cox regression analysis, we calculated
again an optimal threshold for OPN concentrations pre-
dicting patients’ long-term survival, revealing that an OPN
concentration of 2207 ng/ml displayed the best sensitivity
and specificity to predict the patients’ long-term prognosis.
Kaplan-Meier curve analysis for this threshold, for the
threshold of 2500 ng/ml or OPN values of the upper
quartile of all measurements indicated that patients
with low OPN levels had a more favorable prognosis
than those with higher values (Fig. 5e, Figure S1 in
Additional file 2). Patients with OPN levels >2207 ng/ml
showed a significantly higher mortality rate further
underscoring the value of OPN measurements at dayTable 4 Multivariate Cox regression analysis for osteopontin
levels at admission to predict ICU survival
Parameter Unadjusted
HR (95 % CI)
p value Adjusted
HR (95 % CI)
p value
CRP - n.s. - n.s.
WBC - n.s. - n.s.
Bilirubin 1.079 (1.039–1.121) <0.001 - n.s.
INR 2.041 (1.435–2.902) <0.001 1.782 (1.044–3.041) 0.034
Creatinine - n.s. - n.s.
Osteopontin 1.001 (1.000–1.001) 0.009 1.001 (1.000–1.001) 0.009
CI confidence interval, CRP C-reactive protein, INR international normalized
ratio, HR hazard ratio, WBC white blood cell count3 of ICU treatment for the prediction of patients’
prognosis (57 versus 46 %). Youden Index as well as
the likelihood ratios and diagnostic odds ratio for this
cutoff are given in Table S2 in Additional file 1.
Again, we evaluated a “grey zone” with two additional
cutoffs to detect overall death. The first cutoff with OPN
level of 2808 ng/ml corresponds to a high specificity
(sensitivity: 0.29; specificity 0.86). The second cutoff
1486 ng/ml corresponds to a high sensitivity (sensitivity:
0.86; specificity 0.21; Table S1 in Additional file 1).
Of note, multivariate Cox regression analyses, including
markers of inflammation/infection (CRP, WBC), hepatic
(bilirubin, INR) and renal (creatinine) function at day 3,
revealed that OPN represents an independent significant
prognostic parameter also for overall survival (Table 5).
Thus, our data indicate that measurement of OPN levels
in a medical ICU environment might have a valuable role
in the assessment of a critically ill patient’s short-term and
long-term prognosis.
Discussion
In this study, we assessed OPN concentrations upon
admission to the medical ICU before specific therapeutic
interventions and at day 3 after ICU admission in a well-
characterized cohort of critically ill patients [23, 25, 33, 34].
In these patients, OPN serum concentrations were found
to have a close association with the prognosis, espe-
cially if assessed at day 3 after admission to the ICU.
OPN is a secreted phosphorylated protein that exists
as a component of the extracellular matrix and as a
soluble cytokine. Under basal conditions, OPN is bio-
synthesized by various tissue types including osteocytes,
fibroblasts, osteoblasts, smooth muscle and endothelial cells
[35–38]. In the immune system, it is expressed by many cell
types like macrophages, neutrophils, dendritic cells, natural
killer (NK) cells and T and B lymphocytes [39]. OPN’s
capacity to interact with multiple surface receptors suggests
that it is an active player in many physiological and
pathological processes. It is upregulated due to many
different stress stimuli, implying a functional role during
stress response [39]. Its functional relevance in immunity
and during the inflammatory response to infection and cell
damage are well documented [39, 40]. For instance, OPN
plays an important role in chemotaxis and recruitment of
neutrophils and macrophages. Moreover, it modulates cell-
mediated immune reactions by promoting the response of
T helper (Th1)-type CD4+ T cells and driving IL-17
expression [41]. Importantly, OPN modulates immunity
in different directions. Although it is widely designated
as a pro-inflammatory factor, it can also mediate anti-
inflammatory effects under certain conditions [39].
Sepsis and the Systemic Inflammatory Response
Syndrome (SIRS) represent states of profound dysbalance
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log rank 12.40
p < 0.001
Fig. 5 Prediction of long-term mortality by osteopontin serum concentrations. a and b High serum OPN serum levels indicate an impaired
outcome in critically ill patients as patients that survived ICU treatment had lower OPN serum levels after 3 days of ICU treatment (p = 0.035, U test).
Box plot are displayed, where the bold line indicates the median per group, the box represents 50 % of the values, and horizontal lines show minimum
and maximum values of the calculated non-outlier values. c ROC curve analyses comparing the prognostic value of OPN levels at day 3 of ICU
treatment for overall survival (AUC 0.752) with that of the initial SAPS2 – score (AUC 0.647) and day 3 SAPS2 – score (AUC 0.768). d ROC curve
analyses comparing the prognostic value of OPN levels at day 3 of ICU treatment for overall survival (AUC 0.626) with that of WBC (AUC 0.475),
CRP (AUC 0.446), bilirubin (AUC 0.560), INR (AUC 0.621) and creatinine (AUC 0.611). e Kaplan-Meier survival curves of ICU patients showed that
patients with high OPN concentrations had an increased overall mortality compared to other patients. p values for log rank test are given in the
figure. *p <0.05. AUC area under the curve, CRP C-reactive protein, ICU intensive care unit, INR international normalized ratio, OPN osteopontin,
ROC receiver operating characteristic, SAPS Simplified Acute Physiology Score, WBC white blood cell count
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referred to the ICU [23]. The exact pathomechanisms of
sepsis/SIRS are not yet fully understood. The clinical
picture is determined by an excessive inflammatory
response of the immune system to the triggering stimulus,Table 5 Multivariate Cox regression analysis for osteopontin
levels at admission to predict overall survival
Parameter Unadjusted
HR (95 % CI)
p value Adjusted
HR (95 % CI)
p value
CRP - n.s. - n.s.
WBC - n.s. - n.s.
Bilirubin - n.s. 1.056 (1.006–1.109) 0.028
INR - n.s. - n.s.
Creatinine - n.s. - n.s.
Osteoponin 1.001 (1.000–1.001) 0.004 1.001 (1.000–1.001) 0.014
CI confidence interval, CRP C-reactive protein, INR international normalized
ratio, HR hazard ratio, WBC white blood cell countfollowed by a prolonged immunosuppressive state [42].
Both stages of the disease process seem to comprise the
prognosis. However, recent reports imply that especially
the effects of the delayed immunosuppressive phase may
have been underestimated [42]. Both the initiation and
progression of sepsis seems to be orchestrated by activated
T cells, particularly CD4+ T helper 1 (Th1) and Th2 cells
[43]. Moreover, Th17 cells that produce IL-17 have been
demonstrated to play an important role in the regulation
of pro- and anti-inflammatory factors during sepsis [43].
OPN, that is also known as Eta-1 (early T lymphocyte
activation gene 1), is highly expressed in activated T cells.
It has been shown to regulate CD4+ T helper cell lineage
commitment towards the specific Th subtypes [9] and to
drive IL-17 production [41]. Thus, it seems obvious
that OPN exerts important regulatory functions in the
pathogenesis of sepsis. In this regard, Vaschetto and
co-workers have demonstrated increased serum levels
of OPN in patients suffering from sepsis and SIRS
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our data confirm this report showing elevated OPN levels
compared to healthy controls and lower levels of OPN in
surviving versus non-surviving patients. Moreover, our
work extends the results from Vaschetto et al., demon-
strating that OPN correlated significantly better with the
prognosis than “classical” prognostic markers like CRP,
INR and creatinine and also than the sepsis marker PCT.
Of note, Vaschetto et al. even suggested that OPN
serum levels may allow differentiating between sepsis
and SIRS [18]. In contrast, we could not recapitulate a
strong specificity of OPN for the diagnosis of sepsis. In
our study comprising a heterogeneous medical popula-
tion of critically ill patients, there was no significant
difference of OPN levels between patients with or with-
out sepsis. Our results indeed indicate a fundamental
role of OPN in the pathogenesis of inflammatory dysba-
lance of ICU patients, independent of the presence of an
infection. Thus, our report might support the recently
growing notion that the course and prognosis of disease
patterns of ICU patients, like cardiogenic shock or liver
failure, seem to be mainly determined by the patient’s
inflammatory response that self-dynamically develops
beyond the initial pathogenic stimulus [44–46]. In line
with this notion, OPN serum levels correlated both with
markers of liver failure (alkaline phosphatase (AP);
gamma glutamyl transpeptidase (GGT), bilirubin) heart
failure (BNP), clinical scores like APACHE II and SAPS2
as well as novel prognostic markers like APRIL [23] and
circulating miR-133a [25]. In this regard, it is not
surprising that OPN is highly upregulated in conditions
of critical illness upon admission to the ICU. The
striking fact that patients with persistently elevated OPN
levels (at day 3 of ICU treatment), in which OPN do not
regress as usually seen in the cohort (Fig. 2), have a poor
prognosis, is certainly very interesting to investigate on
possible detrimental functions of persistently elevated
OPN during systemic inflammation.
In spite of advances in diagnosis and treatment of
critically ill patients throughout the recent decades, the
triage, diagnostic and therapeutic management of these
patients during the first week of ICU treatment still
represents a major challenge. The promptness and
accuracy of the initial decisions during the initial course
of disease are of immense importance for the subsequent
outcome of sepsis [47] or cardiogenic shock [48].
Inversely, failure of initiating the adequate therapy
during the first phase of the disease may critically
affect the mortality of these patients [23]. In this respect,
the use of novel biomarkers that allow rapid decision-
making with sufficient accuracy may significantly improve
the treatment and finally the outcome of ICU patients [49,
50]. OPN serum levels seem to specifically unfold its
power to predict the prognosis of patients in the earlyphase after ICU admission, thus offering a novel tool
to guide treatment decisions at this critical time-point.
Given that OPN at day 3 of ICU treatment is a strong pre-
dictor of mortality risk, one could speculate that its use
might be implemented into established scoring systems
together with markers that detect the initial cause of the
critical illness leading to ICU admission (e.g. APRIL, which
has recently been demonstrated to specifically detect sepsis
[23], or BNP as a marker of heart failure [51]).
Taken together, our data provide evidence for a role of
OPN as a diagnostic tool in the prognostic judgment of
critically ill and septic patients during the early phase of
their ICU stay. Certainly, these data need to be recapitu-
lated in larger independent cohorts as well as in other ICU
settings such as post-surgery care, before implementation
into clinical algorithms can be considered. Moreover,
although our data imply an important role of OPN in the
molecular pathogenesis in critically ill patients, they do not
provide a specific molecular mechanism of action. OPN
may trigger either pro-inflammatory stimuli like TNF or
IL-6 (Table 3) as well as anti-inflammatory stimuli [9]. In
this regard, a recent study by Fortis et al. demonstrated
that OPN is required for enhanced glucocorticosteroid
production in an animal model of sepsis [52]. In line with
the results from our report, the authors demonstrate that
OPN is associated with a worsened outcome in sepsis in
spite of enhanced glucocorticoid levels, which are thought
to have a beneficial impact in severe sepsis [52]. One might
speculate that in the setting of sepsis, potentially beneficial
targets of OPN are outbalanced by maladaptive effects.
In our study, we assessed a more heterogeneous
population of critically ill patients with different
entities, including sepsis, but also cardiogenic shock
or liver failure. The balance between pro- and anti-
inflammatory effects of OPN might be specifically
regulated in each of these entities. Nevertheless, the
results from our study provide a clear rationale for
future functional studies on the role of OPN in different
disease models related to critical illness.
Conclusions
Our study identifies osteopontin (OPN) as a stable and
robust marker in critically ill patients to assess disease
severity and mortality risks. While OPN serum levels are
elevated compared to healthy controls both at admission
to the ICU and after 3 days of treatment, persistently
elevated OPN levels at day 3 of ICU treatment are a
strong independent predictor for an unfavourable
prognosis. In line with prognostic properties, OPN is
closely correlated to established prognosis scores.
High OPN levels do not discriminate septic patients
from non- septic patients. In contrast, OPN correlates
with experimental markers of general inflammation and
multi-organ failure.
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 Serum levels of OPN in critically ill patients are
elevated compared to healthy controls both at
admission to the ICU and after 3 days of treatment.
 OPN concentrations were related to disease severity
and significantly correlated with established
prognosis scores and classical as well as
experimental markers of inflammation and
multi-organ failure.
 In the total cohort, OPN levels decreased from
admission to day 3 of ICU treatment. However,
persistently elevated OPN levels at day 3 of ICU
treatment were a strong independent predictor for
an unfavourable prognosis and indicated short- and
long-term mortality with higher diagnostic accuracy
than routinely used markers of organ failure and
prognostic scoring systems such as SAPS2 or
APACHE II score.Additional files
Additional file 1: Table S1. Cutoff values for OPN at day 3 to
distinguish between ICU survivors yes vs. no; Table S2. Cutoff values for
OPN at day 3 to distinguish between overall survivors yes vs. no.
Additional file 2: Figure S1. Elevated osteopontin serum levels
indicate poor survival in critically ill patients. a Kaplan-Meier survival
curves of ICU patients showing that patients with OPN levels within
the lower quartile of all patients had a decreased short-term mortality
at the ICU as compared to other patients. b Kaplan-Meier survival curves
of ICU revealed that patients with OPN levels below 2500 ng/ml had a
decreased ICU mortality as compared to patients with higher OPN
serum concentrations. c Kaplan-Meier curve analysis of ICU patients
demonstrates that patients with OPN levels within the upper quartile
had a decreased overall survival as compared to other patients.
d Kaplan-Meier survival curves of ICU patients showed that patients
with high OPN concentrations had an increased overall mortality
compared to other patients. p values are given in the figure.
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